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Context:Commoncommunity-acquired infections, suchas cytomegalovirus (CMV),may contribute
to the development of obesity and metabolic dysfunction, but empirical evidence is scarce.
Objective: We examined the associations between CMV, obesity and metabolic characteristics in
a large, general population-based sample of adults.
Design and setting: An observational study in community dwelling adults from the general pop-
ulation, ‘Understanding Society – the UK Household Longitudinal Study’.
Participants: 9,517 men and women (aged 52.4  16.4 yrs; 55.3% female).
Measures: CMV infection was measured using Immunoglobulin G (IgG) from serum. Obesity was
defined as body mass index 30 kg/m2. Based on blood pressure, HDL-cholesterol, triglycerides,
glycated haemoglobin A1c, and C-reactive protein, participants were classified as ‘healthy’ (0 or 1
metabolic abnormality) or ‘unhealthy’ (2 metabolic abnormalities).
Results: A positive CMV test was recorded in 47.5% of the sample. There was no association
between CMV and obesity. Of the individual metabolic risk factors, CMVwas positively associated
with glycated haemoglobin and HDL-cholesterol. In combination, only ‘unhealthy non-obese’
participants had modestly increased odds of CMV (odds ratio compared to healthy normal-
weight 1.12, 95% confidence interval 1.00 – 1.26) after adjusting for a range of variables. CMV
was associated with an increased prevalence of cardiovascular diseases (odds ratio1.67; 1.07 –
2.60) independently of obesity, metabolic risk factors, and other covariates.
Conclusion:Our findings suggest aweak but statistically significant association between CMV and
metabolic dysfunction in non-obese adults. This relationship appears to be masked in the obese,
possibly by the effects of excess adiposity on metabolism.
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Cytomegalovirus (CMV) is one of the most well-char-acterized infections in humans. This infection is typ-
ically acquired in childhood and is lifelong. Although
CMV rarely causes symptoms, it has been linked to ad-
verse metabolic characteristics, including obesity (1–4)
and factors that accompany this condition, such as im-
paired glucose control and dyslipidaemia (5–12). These
associations are biologically plausible because infection
provokes immune responses, such as the release of inflam-
matory cytokines that have been linked to the etiology of
metabolic disorders including diabetes (13). Infection
with CMV might also contribute to features of immune-
senescence, such as the accumulation of differentiated cy-
totoxic T cells. Some evidence suggests that the accumu-
lation of these cells could drive an unfavourablemetabolic
profile (14). In addition, it has been postulated that excess
adipose tissuemay lead to susceptibility to infections, such
as CMV, (2, 4) through influencing a variety of immune
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mediators. However, the adverse effects of excess adipos-
ity on metabolism might also mask any association be-
tween CMV and metabolic parameters.
Existing data on obesity, metabolic dysfunction and
acquired infections is generally sparse. Most studies have
suffered from methodological weaknesses such as small
sample sizes (n  150), (5, 7–8) case-control rather than
prospective designs, (5, 7–8, 11) and inadequate adjust-
ment for sociodemographic factors. To the best of our
knowledge, no large-scale studies to date have simultane-
ously examined the associations of CMV with both obe-
sity and metabolic health, controlling for potential con-
founding factors, such as poor lifestyle and social
disadvantage, (12, 15) to evaluate the strength of these
associations in the general population and to separate the
possible underlying mechanisms. These associations may
have important clinical implications as CMV infections,
although common, are not routinely subject to screening
and treatment is considered only in the rare event the in-
fection is activated and symptomatic.
Materials and Methods
Understanding Society – the UK Household Longitudinal Study
(UKHLS) – is a large, longitudinal survey of households in the
United Kingdom (England, Scotland, Wales and Northern Ire-
land). In 2010–2012, participants completed a face-to-face in-
terview and nurse health assessments were conducted approxi-
mately fivemonths following completion of the survey interview
(16). In brief, in the general population sample there was a
58.6% response for the nurse assessment component and full
blood sampleswere successfully collected in10 175participants.
Participants gave full informed written consent to participate in
the study and ethical approval was obtained from the Ethics
Committeeof theUniversityofEssex (main survey) andNational
Research Ethics Service Oxfordshire REC A (nurse health
assessment).
Nurse health assessment
Nurses collected anthropometric data (weight, height, waist
circumference), blood pressure (BP), and nonfasting blood sam-
ples using standard protocols. Body weight was measured using
Tanita BF 522 scales without shoes and in light clothing, and
height was measured using a Stadiometer with the Frankfort
plane in the horizontal position. Body mass index (BMI) was
calculated as weight (kilograms)/height (meters) squared. Waist
circumferencewas recorded twice usingmeasuring tapemidway
between the iliac crest and lower rib. An average of the first two
measurements was used provided these differed by nomore than
3cm; otherwise a third reading was taken and the two closest
results utilized. Systolic and diastolic BP was measured with an
Omron HEM-907 BP monitor three times in the sitting position
after 5-minute rest between each reading. The initial readingwas
discarded and an average of the second and third BP recordings
was used for the present analyses. All respondents were eligible
to give blood except pregnant women, individuals who volun-
teered that they areHIV positive or had hepatitis B or C, persons
with clotting or bleeding disorder such as hemophilia, or those
with a self-declared lowplatelet count.Additionally, peoplewho
had ever had a fit, or those taking anticlotting medication (eg,
warfarin) were also excluded. Blood samples were analyzed for
C-reactive protein (CRP), high density lipoprotein (HDL) cho-
lesterol, triglycerides, and glycated hemoglobin (HbA1c). De-
tailed informationon the technicalities of thebloodanalysis have
been described elsewhere (17).
Measurement of Cytomegalovirus (CMV)
antibodies
Immunoglobulin G (IgG) and IgM were measured from se-
rum samples with an electrochemiluminsecent immunoassay
(Roche E170 analyzer). Interand intra-assay coefficients of vari-
ation were acceptable, less than 4%. A positive CMV IgG result
indicates aCMV infection at somepoint in time,while a negative
CMV IgG indicates that the participant has never been exposed
to, or been infected with, CMV. A positive Immunoglobulin M
(IgM) indicates a recent or current infection. Indeterminate
CMV occurs during current or acute infection or may be due to
nonspecific binding. For those people who had a positive IgM
test or whose result was indeterminate, an additional test was
performed to confirm recent CMV infection. This confirmatory
assay was an avidity test on the Mini VIDAS immunoassay
analyzer.
Covariables
Health-related questions included cigarette smoking (cur-
rent; previous; nonsmoker), the frequency of participation in
sports and exercise (more than three times per week; 1 – 3 times
per week; once per month or less; never), and the frequency of
alcohol intake (at least 5–6/wk; 1–4/wk;monthy; rarely /never).
Participants were also asked to state their highest educational
attainment (Degree; A-level/GCSE; other; none) and to rate their
health (excellent; very good; good; fair; poor).
Statistical analyses
Body mass index was categorised into four groups (normal:
from 18.5 to  25 kg/m2; overweight: from 25 to  30 kg/m2;
obese I: from 30 to 35 kg/m2; obese II and more severe forms:
 35 kg/m2). Based on existing criteria (18) unhealthymetabolic
status was defined as having two or more of the following met-
abolic risk factors: high BP (systolic/diastolic BP  130/85
mmHg, or hypertension diagnosis, or use of antihypertensive
medication), impaired glycaemic control (HbA1c 6.0% [42.1
mmol/mol] or doctor’s diagnosed diabetes), systemic inflamma-
tion (CRP3mg/l), lowHDLcholesterol (1.03mmol/l inmen
and  1.30 mmol/l in women), and high triglycerides ( 1.7
mmol/l). Participants were then categorized into four groups:
‘healthy nonobese’; ‘unhealthy nonobese’; ‘healthy obese ’; and
‘unhealthy obese’.
Wecalculatedodds ratios (OR)and95%confidence intervals
(CI) for the odds of CMV in relation to obesity, metabolic status
and their combination. We tested for sex interactions, but as
none were present, men and women were pooled in the same
analysis. Initially,weadjustedour effect estimates for sexandage
(model 1). We further adjusted the models for education, sports
and exercise participation, self-rated health, smoking, and alco-
hol (model 2). Analyses were conducted using SPSS version 22.
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Results
The analytic sample comprised 9517 participants (aged
52.4 16.4 yrs; 55.3% female). A positive CMV test was
apparent in 47.5%of the sample. Participants testing pos-
itive forCMVtended tobeolder, female, smokers, haveno
educational qualifications, and poorer self-rated health
(Table 1). In logistic regression models mutually adjusted
for all variables, per year increase in age (OR; 95% con-
fidence interval (CI): 1.02, 1.01 – 1.03), being female
(1.26; 1.16 – 1.38), a smoker (1.21; 1.07 – 1.37), and no
qualifications (1.72; 1.46 – 2.02) remained associated
with CMV positive status.
There was no association between BMI and CMV (Ta-
ble 2), nor did we observe any association when using
waist circumference as a measure of central obesity (OR
per unit increase 1.00; 0.99 – 1.01, P .94).Metabolic
health was associated with the status of CMV in models
adjusted for age and sex, although after further adjust-
ments the associationwas attenuated to the null (Table 2).
In analyses that combined obesity and metabolic health,
participants defined as “unhealthy nonobese” had in-
creased odds of being CMV positive (Table 2). In further
analyses to examine associations between individual met-
abolic risk factors and CMV we observed significant as-
sociations for HbA1C and HDL-cholesterol (Table 3).
We further examined these associations in relation to a
clinically meaningful outcome; 105 self-reported physi-
cian-diagnosed cases of cardiovascular diseases (CVD)
(including congestive heart failure (CHF), angina/ myo-
cardial infarction (MI)/coronaryheart disease (CHD), and
stroke) were reported. In analyses (Table 4) in which we
adjust our effect estimates for covariates, CMVwas asso-
ciatedwithhigheroddsofCVD(OR1.67, 95%CI,1.07
– 2.60) independently of obesity and metabolic risk
factors.
Discussion
Our main finding was an association between CMV and
the individual metabolic risk factors of high glycated he-
moglobin and low HDL-cholesterol. However, only met-
abolically ‘unhealthy nonobese’ participants had an in-
creased prevalence of the acquired infection. In contrast,
CMV was not associated with metabolic health in obese
participants and therewas no association between obesity
and CMV. In further analyses using a clinical endpoint,
CMV was associated with CVD independently of obesity
and metabolic risk factors.
Existing data on metabolic health and acquired infec-
tions is generally sparse. Most studies have suffered from
methodological weaknesses such as small sample sizes
(n  150), (5, 7–8) case-control rather than prospective
designs, (5, 7–8, 11) and inadequate adjustment for so-
ciodemographic factors.With over 9000 participants, our
study is, to the best of our knowledge, the largest popu-
lation-based study on CMV in relation to a range of met-
abolic factors and obesity.
Obesity is thought to influence the immune response
that has been hypothesized to increase susceptibility to
infections (2, 4). However, the most plausible interpreta-
tion of our findings is that the accumulation of viral load
and associated immune activation is driving an unfavour-
able metabolic profile among nonobese. Obesity often
precedes metabolic dysfunction, (19) thus in obese par-
ticipants is likely to be the strongest driver of metabolic
Table 1. Characteristics of the sample
according to CMV status (n  9517)
Variable
CMV positive
(n  4524)
CMV negative
(n  4993)
p-
value
Age (yrs) 56.4  16.0 48.6  15.8 0.001
Sex (%) 0.001
Men 41.9 47.3
Women 58.1 52.7
Education (%) 0.001
Degree 30.3 38.8
A-level/GCSE only 37.7 43.3
Other 13.3 9.4
No qualification 18.7 8.5
Smoking (%) 0.002
Never 37.9 41.5
Ex-smoker 42.3 40.0
Current 19.7 18.4
Sports and exercise
participation (%)
0.001
Never 39.7 27.8
Once a month or
less
27.4 33.7
At least once a
week
19.3 22.3
More than three
times a week
13.6 16.4
Frequency of
Alcohol intake
(%)
0.001
At least 5–6 times
a week
16.4 14.9
Weekly 41.4 47.8
Monthly 14.4 15.6
Rarely/never 27.8 21.7
Self--rated health
(%)
0.001
Excellent/very good 47.2 55.1
Good 29.9 28.3
Poor/fair 23.0 16.6
Body mass index
(kg/m2)
28.4  5.3 28.0  5.6 0.001
Number of
metabolic risk
factors
1.4  1.2 1.2  1.1 0.001
doi: 10.1210/jc.2015-4208 press.endocrine.org/journal/jcem 3
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 22 February 2016. at 05:34 For personal use only. No other uses without permission. . All rights reserved.
risk and might explain why the ‘unhealthy obese’ were
seeminglynotat elevated riskofCMVinfection in contrast
to their nonobese counterparts.
Associations between CMV andmetabolic health were
attenuated after adjustment for social and lifestyle factors,
suggesting these relationships could be part of a causal
pathway starting from social determinants of health. This
is consistent with findings from a previous population
sample of US adults demonstrating that the association
between CMV and diabetes was attenuated to the null in
models accounting for social and lifestyle factors (12).
CMVwas, however, associated with CVD independently
of covariates; this is consistent with prior evidence (20).
CMV is known to increase experimental atherosclerosis
and to modulate vascular-wall activity, (21, 22) thus the
association is likely to be independent of adiposity and
metabolic dysfunction.
Infection causes immune responses, such as the release
of inflammatory cytokines that have been linked to the
etiology of metabolic disorders including diabetes (13).
Table 2. Odds ratios (95% confidence interval) for the relation between obesity, metabolic health and history of
CMV infection (n  9517)
CASES/N
Model 1 OR
(95% CI)
Model 2 OR
(95% CI)
Obesity
Normal (18.5 to 25
kg/m2)
1198/2679 1.0 (Ref) 1.0 (Ref)
Overweight (25 to 
30 kg/m2)
1871/3893 1.02 (0.92 – 1.13) 1.03 (0.93 – 1.15)
Obese I (30 to 35
kg/m2)
976/1957 1.08 (0.95 – 1.22) 1.06 (0.93 – 1.20)
Obese II (35 kg/m2) 499/993 1.12 (0.96 – 1.30) 1.04 (0.89 – 1.22)
p-linear trend 0.10 0.52
Metabolic health?
Healthy (0 or 1 risk
factor)
2658/5956 1.0 (Ref) 1.0 (Ref)
Unhealthy (1 risk
factor)
1891/3584 1.15 (1.05 – 1.25) 1.05 (0.95 – 1.15)
p-linear trend
(continuous score)
0.002 0.41
Metabolic health/
obesity
Healthy non-obese 2105/4785 1.0 (Ref) 1.0 (Ref)
Unhealthy non-
obese
963/1784 1.22 (1.08 – 1.36) 1.12 (1.00 – 1.26)
Healthy Obese 546/1151 1.13 (0.99 – 1.29) 1.11 (0.97 – 1.27)
Unhealthy Obese 927/1797 1.14 (1.02 – 1.28) 1.04 (0.92 – 1.17)
Model 1: adjusted for age and sex
Model 2: adjusted for age, sex, education, sports and exercise participation, self rated health, smoking, alcohol.
defined from: High blood pressure (clinic BP 130/85 mmHg, or hypertension diagnosis, or use of anti-hypertensive medication), impaired
glycaemic control (HbA1c  6.0% or doctor’s diagnosed diabetes), systemic inflammation (C-reactive protein 3 mg/liter), low HDL cholesterol
(1.03 mmol/liter in men and 1.30 mmol/liter in women), and high triacylglycerol (1.7 mmol/liter).
Table 3. Odds ratios (95% confidence interval) for the relation between individual metabolic risk factors and CMV
infection
Risk factor
(per standard deviation increase)†
Model 1
(OR, 95% CI)
Model 2
(OR, 95% CI)
HbA1c (8.0 mmol/mol) 1.08 (1.03 – 1.13) 1.01 (1.00 – 1.02)
HDL-Cholesterol (0.46 mmol/liter) 0.91 (0.87 – 0.95) 0.80 (0.71 – 0.90)
Triglycerides (1.10 mmol/liter) 1.03 (0.98 – 1.08) 0.99 (0.94 – 1.03)
C-Reactive Protein (6.75 mg/liter) 1.02 (0.99 – 1.07) 1.00 (0.99 – 1.02)
Systolic Blood Pressure (16.3 mmHg) 0.95 (0.81 – 1.12) 0.94 (0.80 – 1.11)
†a standard deviation increase denoted after variable
Model 1: adjusted for age and sex
Model 2: adjusted for age, sex, education, sports and exercise participation, self rated health, smoking, alcohol, BMI, and mutually for other
metabolic risk factors.
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Interestingly, we found no association between CRP and
CMV, but the link with metabolic health was driven by
HDL-cholesterol and HbA1C. This suggests mechanisms
other than inflammatory response related to innate im-
munitymayprimarily drive the association betweenCMV
and metabolic dysfunction. Recent evidence has shown
the accumulation of differentiated cytotoxic T cells in
CMV positive participants was associated with HbA1C
and cholesterol, (14) suggesting a direct role of the im-
mune cells related to the adaptive immune system.
There are several limitations. Firstly this is a cross-sec-
tional study thus we can only speculate on the causality
anddirection of our findings. Second, ourmeasurement of
pathogen infection was based on seropositivity to IgG an-
tibodies, which reflects prior infection, but are not sensi-
tive indicators of current infection or the chronicity of
prior infections.Nevertheless, active pathogen infection is
unlikely to have influenced our results as recent infection
(measured through positive IgMand confirmatory avidity
test) was apparent in less than 0.5% of the sample and
removal of these participants did not influence the present
results (data not shown). Detailed assessments of immune
activity were not possible in the present study. An assess-
ment of T cell pattern in participants with positive or neg-
ative CMV test would provide further hints as to how
CMV infection impacts on immune cell function driving
an unfavourable metabolic profile (23).
In summary, we demonstrated no association between
obesity and CMV. We identified a weak but statistically
significant association between CMV and metabolic dys-
function in nonobese adults, but not in their obese coun-
terparts.We speculate that in thenonobeseCMVinfection
may drive metabolic dysfunction whereas in the obese
population excess adiposity is themain cause ofmetabolic
disturbance. As any associations observed with metabolic
risk factors were weak, our findings do not justify univer-
sal screening of CMV to prevent diabetes, although there
appears to be a stronger association between CMV and
CVD.
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